Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE

All products: general benefit

Enstilar · DIN 02457393 · 50mcg/g & 0.5mg/g · Top Aero Foam

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Enstilar · DIN 02457393 Manufacturer: Leo Pharma Inc.; listing date 2018-10-31 Health Canada: Marketed since 2016-11-11 · brand ENSTILAR · ATC D05AX52 CALCIPOTRIOL, COMBINATIONS · form Aerosol (foam) · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G, CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) 50 MCG/G · company Leo pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Enstilar: Formulary list price $1.6412/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6412 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94445 · Verify on the e-Formulary ↗ (DIN 02457393)

Source record
DIN 02457393: Enstilar Raw flags: sec3=Y Item: 840600154; group id 840; item number 2044; lccId None; manufacturer id LEO Source form: Top Aero Foam; strength: 50mcg/g & 0.5mg/g Recorded listing: General benefit Source prices (unrounded): $1.6412; ministry $1.6412 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457393 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94445 Therapeutic Notes (formulary) For the treatment of moderate to severe scalp psoriasis in patients who have failed first-line topical corticosteroid therapy. For the treatment of mild to moderate body psoriasis in patients who have failed first-line topical corticosteroid therapy and Dovonex (calcipotriol) therapy.
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered

Matched class: 84:06 Anti-Inflammatory

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:06 Anti-Inflammatory

AMCINONIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.1% · Cr

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 0.025% · Cr, Oint

BETAMETHASONE DIPROPIONATE

· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint

BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL

· 2 products · General benefit · strengths: 0.05% · Oint

BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE

· 2 products · General benefit · strengths: 0.05% · Cr

BETAMETHASONE VALERATE

· 19 products · Listed, not a benefit (7), General benefit (12) · strengths: 0.05%, 0.1% · Cr, Lot, Oint, Scalp Lot

CLOBETASOL PROPIONATE

· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp

DESONIDE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.05% · Cr, Oint

FLUOCINONIDE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 0.05% · Cr, Emol Cr, Gel, Oint

HALOBETASOL PROPIONATE

· 1 products · General benefit · strengths: 0.01% w/w · Lot

HYDROCORTISONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.5%, 1% · Oint

HYDROCORTISONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06 and 5 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:28 Keratolytic Agents, 84:36 Miscellaneous Skin and Mucous Membrane Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications DOVOBET (calcipotriol and betamethasone dipropionate) ointment is indicated for: • the topical treatment of psoriasis vulgaris for up to 4 weeks. 1.1. Pediatrics Pediatrics (< 18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (≥ 65 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00085846.PDF PM date: 2026-08-21 Source product: DOVOBET OINTMENT; DIN 02244126; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.